May 18, 2026

The Bloating and SIBO Side Effect of Retatrutide (RETA), Ozempic & Mounjaro Nobody's Talking About

A research-grounded look at why GLP-1 weight loss medications can disrupt your gut — and what the science actually says is happening.

Medical disclaimer. This article is for educational purposes only and is not medical advice, diagnosis, or treatment. It does not establish a clinical relationship. Retatrutide (RETA) is an investigational drug currently in clinical trials and is not FDA-approved as of this writing. Other medications discussed — semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) — are FDA-approved but should only be used under physician supervision. Do not start, stop, change, or combine any medication, supplement, or protocol based on what you read here. Always talk with your prescribing physician or a qualified healthcare provider before making decisions about GLP-1 medications, gut symptoms, or supplementation. Statements in this article have not been evaluated by the FDA. Luna Lab products are not intended to diagnose, treat, cure, or prevent any disease.

The short version

If you're on a GLP-1 medication — Ozempic, Wegovy, Mounjaro, Zepbound, or the newer retatrutide (RETA) — and your gut has been a mess since you started, you're not imagining it. And it's not just "nausea while you adjust."

There's a specific, well-documented chain reaction these drugs set off in your digestive system. They dramatically slow how food moves through your stomach and small intestine. That slowing, over weeks and months, creates the exact conditions research has identified in the development of SIBO — small intestinal bacterial overgrowth.

The bloating, gas, food sensitivities, and that "everything I eat makes me uncomfortable" feeling many GLP-1 users describe? It's not random. It's mechanism.

This article walks through what's actually happening in your gut, why almost nobody is connecting these dots, and what the research says about it.

What GLP-1 medications are, briefly

GLP-1 receptor agonists are a class of injectable medications originally developed for type 2 diabetes and now widely used for weight loss. The most common ones:

Semaglutide — sold as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form). Targets the GLP-1 receptor.
Tirzepatide — sold as Mounjaro (diabetes) and Zepbound (weight loss). Targets two receptors: GLP-1 and GIP.
Retatrutide (RETA) — investigational, made by Eli Lilly, currently in Phase 3 trials. Targets three receptors: GLP-1, GIP, and glucagon. Not FDA-approved, but already accessed by many people through clinical trials and compounded sources. In Phase 2 trials, retatrutide produced average weight loss in the 24% range — the largest effect of any drug in this class so far.

All three work, in part, by mimicking GLP-1, a natural gut hormone your body releases after eating. Among other things, GLP-1 slows how quickly your stomach empties. These drugs amplify that effect dramatically.

Retatrutide is the most potent of the three, which means — by the same logic that drives its weight-loss effectiveness — its gut effects are likely to be the most pronounced.

What everyone agrees on: GLP-1 drugs slow your digestion

This part isn't controversial. The FDA-approved prescribing information for these medications explicitly lists delayed gastric emptying as a primary mechanism. Clinical research has measured it directly:

Roughly 30% delays in gastric emptying have been reported with semaglutide at typical doses.
In a retrospective study of over 35,000 patients undergoing upper endoscopy, GLP-1 users had a 4-fold higher rate of retained gastric contents compared to non-users (13.6% vs 2.3%) — even after standard overnight fasting.
Multiple bedside ultrasound studies have shown residual stomach contents in GLP-1 users at times when their stomachs should be empty.
For tirzepatide specifically, gastric emptying delay was strong enough that the FDA label warns oral contraceptives may not be absorbed reliably — patients are told to use backup contraception during initiation and dose increases.

For weight loss, this slowed emptying is the goal. You feel full longer. You eat less. The medication is doing its job.

The problem is what happens downstream when that slowing continues, day after day, for months.

Where it gets less talked about: the migrating motor complex (MMC)

This is the part that gets glossed over in most GLP-1 articles, but it's the bridge to understanding why bloating and SIBO show up.

Your small intestine has a built-in housekeeping system called the migrating motor complex, or MMC. It's a series of muscular contractions that sweep through your stomach and small intestine roughly every 90 to 120 minutes — but only when you're not eating.

Between meals, during true fasting windows, the MMC acts like a janitor. It pushes residual food particles, debris, and any bacteria that have drifted up from your large intestine back down where they belong. A 2015 review in the American Journal of Physiology described the MMC as "the intestinal housekeeper that prevents SIBO." Researchers at Cedars-Sinai have shown that people with IBS experience these cleansing waves roughly 70% less often than healthy controls.

Here's the critical point: the MMC only runs during fasting. If there's food in your upper digestive tract, the MMC doesn't fire. Your gut stays in "fed mode."

Now think about what GLP-1 medications do. They keep food in your stomach for hours longer than normal. They extend the post-meal window dramatically. If your stomach normally empties in 2 hours and now takes 5 or 6 hours, you've potentially lost two or three full MMC cycles per day.

Over weeks and months, that adds up to a small intestine that almost never gets swept clean.

What SIBO is, and why this matters

SIBO — small intestinal bacterial overgrowth — happens when bacteria that normally live in your large intestine migrate up into your small intestine and start fermenting your food before you can absorb it.

Your small intestine is supposed to stay relatively bacteria-light. Roughly 98% of your gut bacteria belong in the large intestine, only about 2% in the small. The MMC is one of the main mechanisms keeping that ratio in place.

When the MMC stops sweeping, bacteria stop getting moved along. They settle in. They multiply. And they ferment everything you eat.

That fermentation produces gas — hydrogen, methane, or hydrogen sulfide — in a part of the intestine that wasn't built for it. The result is the symptom cluster GLP-1 users keep reporting:

Bloating that gets worse through the day. Often visible distension. Stomach looks pregnant by evening.
Excessive or unusual gas. Sometimes sulfurous, sometimes just "different than normal."
Abdominal pain or cramping that doesn't track with the initial nausea-during-titration pattern.
New food intolerances. Things you used to handle — onions, garlic, beans, fruit, dairy — now make you miserable.
Alternating diarrhea and constipation, sometimes within the same day.
Brain fog and fatigue that go beyond what calorie reduction alone would explain.

Sound familiar? This is the cluster many people on Ozempic, Mounjaro, and retatrutide describe to their doctors — and often get told "it's just a side effect, it'll pass."

Sometimes it does pass, as the body adapts to the drug. Sometimes it doesn't. And when it doesn't, SIBO is one of the underlying explanations clinicians should be considering.

So does retatrutide actually cause SIBO?

Honest answer: as of this writing, there are no published studies specifically testing whether retatrutide causes SIBO. Same for semaglutide and tirzepatide — direct SIBO-incidence research on GLP-1 users is still emerging.

What we do have:

Robust evidence that GLP-1 medications slow gastric emptying and disrupt normal gut motility.
Robust evidence that impaired motility — particularly impaired MMC function — is one of the primary mechanisms in the development of SIBO. This connection has been documented since the 1970s.
Growing anecdotal reporting from patients describing SIBO-like symptoms after months on these medications.
A clear physiological hypothesis connecting the two that hasn't yet been rigorously tested in a clinical trial.

This is what scientists call "mechanistically plausible but not clinically confirmed." The dots connect logically. The dots haven't been formally measured yet.

But here's what makes this worth taking seriously now rather than waiting for trials to finish: the people most likely to develop this — long-term GLP-1 users on increasing doses — are exactly the population growing fastest. Retatrutide is more potent than semaglutide and tirzepatide. As use expands and treatment durations get longer, the underlying motility disruption gets longer too.

This is the side effect nobody's loudly talking about because it doesn't show up in 12-week trial endpoints. It shows up months in.

Why your doctor might not be connecting these dots

A few honest reasons:

GI side effects are expected with GLP-1 drugs. When a patient reports bloating, the standard playbook is "this is normal, it'll improve with adjustment." Which is often true. But for the subset where it doesn't improve, the playbook stops.
SIBO testing isn't standard in primary care. It requires a hydrogen/methane breath test, which many primary care doctors don't order routinely. You typically need a gastroenterologist or functional medicine practitioner to push for it.
The research is recent. The deep dive on GLP-1 effects on the lower gut microbiome is still being written. The MMC-SIBO connection is well-established in the gastroenterology literature, but the GLP-1 piece linking the two is still emerging.
Your doctor is rightly focused on the bigger picture. The weight loss or diabetes management benefits of GLP-1 drugs are substantial. Gut symptoms are real but, from a doctor's perspective, often not the leading concern.

That doesn't mean you have to accept months of bloating and discomfort as the price of weight loss. It means you may need to bring the SIBO conversation up yourself.

Symptoms worth raising with your doctor

Not every GI symptom on a GLP-1 medication is SIBO. Many are normal adjustment effects that resolve as your body adapts to the drug. But certain patterns are worth flagging:

Bloating that gets worse through the day rather than improving, particularly with visible distension
Gas that's excessive, sulfurous, or significantly different from your baseline
New food intolerances — especially to fermentable carbohydrates (FODMAPs: onions, garlic, wheat, beans, certain fruits, lactose)
Bloating, gas, or pain that doesn't improve after 8–12 weeks on a stable dose
Brain fog or fatigue disproportionate to your calorie reduction
Bowel patterns that don't match the early-medication picture anymore (i.e., not nausea during titration — different and persistent)

If these fit, ask your doctor specifically about a hydrogen/methane breath test for SIBO. It's relatively simple, non-invasive, and inexpensive. A positive result changes the conversation about what's happening in your gut.

What you can actually do

This is the part where most articles on this topic punt. Real answers worth discussing with your doctor:

1. Meal spacing. Some clinicians recommend 3–4 hour gaps between meals and avoiding snacking, which lets the MMC fire between meals even when gastric emptying is slow. Not appropriate for everyone — depends on your overall situation — but worth asking about.

2. Fiber and hydration. GLP-1 users often reduce food and fluid intake dramatically. Both matter for normal motility. Soluble fiber (oats, psyllium, chia) and adequate water aren't trivial — they're functional.

3. Stress management. The MMC is heavily regulated by the vagus nerve. Chronic stress shuts it down independently. People on GLP-1s often add stress (rapid life changes, body image shifts, food restriction). Worth attending to.

4. SIBO breath testing if symptoms persist beyond the typical adjustment window.

5. Prokinetic medications. In some cases, doctors prescribe drugs that stimulate MMC function to counteract the GLP-1's motility-slowing effect. This is a physician-only decision but worth knowing it exists.

6. Dose adjustment. Sometimes a slower titration or temporary dose hold resolves persistent gut issues without losing therapeutic benefit. Your doctor can guide this.

We can't give you medical guidance on any of this. Your doctor can.

Where gut support fits in

Outside of medication decisions — which belong with your doctor — general gut health support is an area where the science is well-established and the interventions are low-risk for most people.

At Luna Lab, we make doctor-formulated protocols designed to support general gut health. Our Microbiome Balance Formula is a 30-day pre-dosed protocol built around a 5R framework (Remove, Replace, Reinoculate, Repair, Rebalance) for people exploring microbial balance support. It includes clinical doses of Berberine, L-Glutamine, organic Ginger Root (a botanical with prokinetic properties), and a multi-strain probiotic blend.

To be clear: we are not suggesting Microbiome Balance Formula treats SIBO, treats any GLP-1 side effect, or should be combined with retatrutide, Ozempic, Mounjaro, or any prescription medication. That's a conversation for you and your doctor.

We're saying: if you're thinking about gut health support more broadly, our research-led formulations may be a useful starting point — and our Library has more in-depth articles on SIBO, the gut lining, and the microbiome generally that you might find worth reading.

The takeaway

Retatrutide and the rest of the GLP-1 class are remarkable drugs for the conditions they're designed to treat. Millions of people benefit from them.

They also, by the nature of how they work, create conditions in the gut — slowed emptying, suppressed MMC function, longer transit times — that overlap exactly with the mechanisms research has identified in the development of SIBO.

That connection is mechanistic, plausible, and consistent with what huge numbers of GLP-1 users are reporting in real life. It's not yet a proven causal link in a published clinical trial. The right response isn't panic. It's informed awareness: know what symptoms warrant a conversation with your doctor, know that there's a real biological reason behind any persistent gut changes you're experiencing, and don't assume "this'll pass" is the only possible answer.

If you're on a GLP-1 medication and your gut isn't right — bring it up. Push for a SIBO breath test if the pattern fits. The side effect that "nobody's talking about" is finally starting to get talked about. Make sure your doctor is part of the conversation.

FAQs

How long does GLP-1 bloating last? For most people, the initial bloating and GI side effects improve within 4–8 weeks as the body adapts to the medication. For a meaningful subset, they don't fully resolve — and that's when the underlying motility and microbiome changes may have created a downstream issue like SIBO worth investigating.

Can Ozempic cause SIBO? There's no published study directly testing this yet. What's known: Ozempic (semaglutide) significantly slows gastric emptying and disrupts the migrating motor complex, both of which are well-documented mechanisms in the development of SIBO. The mechanistic link is plausible. Direct clinical evidence is still emerging.

Why is my bloating worse on retatrutide than on semaglutide? Retatrutide is more potent than semaglutide — it targets three receptors (GLP-1, GIP, and glucagon) versus semaglutide's one. By the same mechanism that makes it more effective for weight loss, its effect on gastric emptying and gut motility is likely more pronounced. More slowing means more time for downstream gut issues to develop.

Will my gut go back to normal after stopping a GLP-1? GLP-1 effects on gastric emptying are reversible — within weeks of discontinuation, motility typically returns toward baseline. However, if SIBO or another downstream gut condition has already developed, that may need to be addressed separately even after the medication is stopped. Talk to your doctor.

Is there a SIBO test I can ask my doctor for? Yes — a hydrogen/methane breath test. It's non-invasive (you drink a sugar solution and breathe into collection bags over a few hours) and is the standard screening for SIBO. Many primary care doctors don't order it routinely; a gastroenterologist or functional medicine practitioner is more likely to.

What's the difference between Ozempic, Wegovy, Mounjaro, Zepbound, and retatrutide? Ozempic and Wegovy are both semaglutide (different doses, different FDA-approved uses). Mounjaro and Zepbound are both tirzepatide. Retatrutide is a separate, newer drug. All work through GLP-1 receptor activation. Tirzepatide adds GIP activation; retatrutide adds both GIP and glucagon. The motility-slowing effect is present across all of them, with potency generally tracking the weight-loss potency.

References & further reading

Camilleri M, et al. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of Clinical Endocrinology & Metabolism.
Deloose E, Janssen P, Depoortere I, Tack J. (2015). Redefining the functional roles of the gastrointestinal migrating motor complex and motilin in small bacterial overgrowth and hunger signaling. American Journal of Physiology - Gastrointestinal and Liver Physiology.
Vantrappen G, Janssens J, Hellemans J, et al. (1977). The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. Journal of Clinical Investigation.
Stotzer PO, Björnsson ES, Abrahamsson H. (1996). Interdigestive and postprandial motility in small-intestinal bacterial overgrowth. Scandinavian Journal of Gastroenterology.
Eli Lilly Phase 2 trial publications on retatrutide (LY3437943), New England Journal of Medicine, 2023.

All articles in The Library are for educational purposes only and not a substitute for professional medical advice.

About the Luna Lab Research Team. Luna Lab is a doctor-formulated supplement brand based in Hawaii. Our protocols are developed in collaboration with practicing physicians including Dr. Andrew Brandeis (Primary Care) and Dr. Todd Born, ND, CNS. Learn more at lunalab.shop.

Back to The Journal